What the FDA labels say about taking them together
Pazopanib and pemetrexed
Pazopanib's FDA label of December 16, 2025 names pemetrexed in its warnings and precautions section; the pemetrexed labels PlainMeds reads (4) do not name pazopanib. The pazopanib label: “Clinical trials of VOTRIENT in combination with pemetrexed and lapatinib were terminated early due to increased toxicity and mortality.”
Check it at the source: the pazopanib FDA label on DailyMed (effective December 16, 2025, Novartis Pharmaceuticals Corporation); the pemetrexed FDA label on DailyMed (effective October 8, 2025, Avyxa Pharma, LLC).
What does the pazopanib label say about pemetrexed?
Pazopanib label, warnings and precautionsClinical trials of VOTRIENT in combination with pemetrexed and lapatinib were terminated early due to increased toxicity and mortality.
Source: FDA drug label (VOTRIENT), Novartis Pharmaceuticals Corporation, effective December 16, 2025 (SPL set eeaaaf38-fb86-4d9f-a19d-0f61daac2fd7), via openFDA; the full label on DailyMed
What does the pemetrexed label say about pazopanib?
Pemetrexed's label (effective October 8, 2025) and its 3 other brand-application labels do not name pazopanib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (AXTLE), Avyxa Pharma, LLC, effective October 8, 2025 (SPL set 9582c46c-d8b0-44b7-a2ee-9c86f5e9b7b1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Pazopanib | Pemetrexed | |
|---|---|---|
| Labeled for | n/a | Lung cancer |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once